I read a study a few years back that said 40% of PWC have Lyme, so it is not everyone with CFS. Also, Lyme is hard to treat if you have bad detox genetics, as most PWC have. Probably we need to get the CFS managed and our immune system working again before we are likely to make much of a dent in Lyme. True, that culture of the 30/33 was interesting, but the culture uses antibodies, which has some issues: 1) WPI used MuLV antibodies and according to one review of research, some MuLV antibodies cross-react with some HERV types, and PWC have high rates of activated HERV per the WPI May presentation and also per research at Tufts; 2) WPI did not publish their results of the antibody study for the control group, so we do not know whether that 30/33 is unique for CFS, or whether the MuLV antibody would have also found an antigen at that rate in the controls. They can cite the literature for standard control rates of positive on MuLV antibodies, but that does not validate their antibody test, they have to run controls in their lab using their reagents, the same test must be run on both the CFS samples and controls. Maybe WPI did that but it was not reported in their Science article. Yes, too early to be making assumptions. Also, a negative result on a standard PCR is pretty strong. False positives are more common than false negatives for the type of PCR test that WPI used. I have heard that VIP is using one of the original prostate cancer tests, which I believe was standard PCR. We do need to keep hope alive. But hope should always be based on what is or can be reality. We do not yet know if XMRV is reality for CFS. So for me anyway my hope is that regardless of the outcome of the XMRV replications, more productive CFS research is in our future.